Your session is about to expire
← Back to Search
Selective Serotonin Reuptake Inhibitor
2 for Depression
Phase 4
Waitlist Available
Led By Mark J Rapoport, MD, FRCPC
Research Sponsored by Ontario Neurotrauma Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
Pivotal Trial
All Individual Drugs Already Approved
Drug Has Already Been Approved
Summary
The purpose of the study is to explore to what extent continuing the antidepressant medication citalopram (Celexa), after depression has responded to treatment, helps prevent the return of depressive symptoms in patients with recent traumatic brain injury (TBI).
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 2Experimental Treatment1 Intervention
Group II: 1Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Citalopram
FDA approved
Find a Location
Who is running the clinical trial?
Ontario Neurotrauma FoundationLead Sponsor
23 Previous Clinical Trials
1,106 Total Patients Enrolled
3 Trials studying Depression
200 Patients Enrolled for Depression
Mark J Rapoport, MD, FRCPCPrincipal InvestigatorSunnybrook Health Sciences Centre, University of Toronto
Share this study with friends
Copy Link
Messenger